|
DHX40 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.10319997581598E-09 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.66419999950251E-07 |
| Normal-vs-Stage2 |
3.501500E-03 |
| Normal-vs-Stage3 |
2.6878499426175E-12 |
| Normal-vs-Stage4 |
1.67849956156374E-10 |
| Stage1-vs-Stage2 |
1.695840E-01 |
| Stage1-vs-Stage3 |
4.043100E-03 |
| Stage1-vs-Stage4 |
3.319600E-03 |
| Stage2-vs-Stage3 |
8.198200E-04 |
| Stage2-vs-Stage4 |
8.415600E-04 |
| Stage3-vs-Stage4 |
5.164200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.61199950557511E-10 |
| Normal-vs-AfricanAmerican |
2.163200E-03 |
| Normal-vs-Asian |
5.63209999999703E-05 |
| Caucasian-vs-AfricanAmerican |
3.959600E-01 |
| Caucasian-vs-Asian |
2.547400E-01 |
| AfricanAmerican-vs-Asian |
9.908600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.75790004774967E-09 |
| Normal-vs-Female |
1.16939999905696E-08 |
| Male-vs-Female |
7.764000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.69369999997371E-06 |
| Normal-vs-Age(41-60Yrs) |
4.29019997305602E-09 |
| Normal-vs-Age(61-80Yrs) |
8.34780022884729E-10 |
| Normal-vs-Age(81-100Yrs) |
3.161900E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
2.296400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
7.891600E-02 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
4.949400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
4.729200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
7.236400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.197200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.90930000000456E-05 |
| Classical-VS-Follicular |
1.202300E-02 |
| Classical-VS-Other |
7.494800E-01 |
| Classical-VS-Normal |
5.88479998064884E-09 |
| Tall-VS-Follicular |
1.71990000019662E-07 |
| Tall-VS-Other |
1.065640E-01 |
| Tall-VS-Normal |
3.57081031410189E-12 |
| Follicular-VS-Other |
2.904400E-01 |
| Follicular-VS-Normal |
2.439100E-03 |
| Other-VS-Normal |
1.177610E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.74649999995502E-06 |
| Normal-vs-N1 |
8.55479997952102E-09 |
| N0-vs-N1 |
5.324000E-02 |
|
|
